Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.
We characterized voriconazole concentrations in the cerebrospinal fluid (CSF) of immunocompetent guinea pigs and patients with invasive fungal infections. In animals, after receipt of oral doses of 4 or 10 mg/kg every 8 h, the mean ratios of CSF to plasma total and free drug concentration were 0.68 and 1.3, respectively. In humans, 1-10 h after receipt of voriconazole, the CSF concentrations ranged from 0.08 to 3.93 microg/mL, and the ratio of CSF to plasma concentration ranged from 0.22 to 1.0 (median, 0.46).
Lutsar
Irja
I
Pfizer, Sandwich, UK. Irja_Lutsar@sandwich.pfizer.com
Roffey
Sarah
S
Troke
Peter
P
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism; D001921:Brain / Q000378:metabolism* / Q000473:pathology*; D001923:Brain Chemistry; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*; D011743:Pyrimidines / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid*; D014230:Triazoles / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole